Ballentine Partners LLC Trims Position in Abbott Laboratories $ABT

Key Points

• Ballentine Partners reduced its Abbott Laboratories position by 19.8% in the second quarter, selling 9,010 shares and retaining 36,598 shares valued at approximately $3.32 million. Institutional investors overall own 75.18% of the company, with several major firms increasing their stakes.
• Abbott reported quarterly EPS of $1.31, beating estimates of $1.28, while revenue rose 13% year over year to $12.59 billion. Management guided for third-quarter EPS of $1.38–$1.46 and full-year 2026 EPS of $5.45–$5.60.
• The company declared a quarterly dividend of $0.63 per share, equivalent to a 2.3% yield, while analysts maintain a “Moderate Buy” consensus and an average price target of $118.67.

Ballentine Partners LLC decreased its position in Abbott Laboratories (NYSE:ABT - Free Report) by 19.8% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 36,598 shares of the healthcare product maker's stock after selling 9,010 shares during the quarter. Ballentine Partners LLC's holdings in Abbott Laboratories were worth $3,321,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Vanguard Group Inc. raised its position in Abbott Laboratories by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker's stock worth $21,995,501,000 after acquiring an additional 2,402,408 shares during the period. State Street Corp grew its position in shares of Abbott Laboratories by 2.1% during the 4th quarter. State Street Corp now owns 79,853,782 shares of the healthcare product maker's stock valued at $10,004,880,000 after acquiring an additional 1,627,791 shares during the period. Capital International Investors increased its stake in shares of Abbott Laboratories by 2.6% in the 4th quarter. Capital International Investors now owns 63,229,445 shares of the healthcare product maker's stock worth $7,922,519,000 after purchasing an additional 1,614,706 shares in the last quarter. J. Stern & Co. LLP raised its holdings in Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker's stock worth $4,926,279,000 after purchasing an additional 39,005,451 shares during the period. Finally, Capital Research Global Investors raised its holdings in Abbott Laboratories by 1.0% in the 4th quarter. Capital Research Global Investors now owns 39,169,239 shares of the healthcare product maker's stock worth $4,907,523,000 after purchasing an additional 400,400 shares during the period. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Up 0.0%

NYSE ABT opened at $111.27 on Monday. The stock's 50 day moving average is $97.67 and its 200 day moving average is $99.77. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The stock has a market cap of $192.53 billion, a PE ratio of 36.01, a P/E/G ratio of 2.15 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company's revenue was up 13.0% on a year-over-year basis. During the same period last year, the firm posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts predict that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be paid a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories's payout ratio is presently 81.55%.

Analyst Ratings Changes

Several research firms have issued reports on ABT. UBS Group cut their price target on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating for the company in a report on Tuesday, July 28th. TD Cowen reaffirmed a "buy" rating and set a $115.00 price objective on shares of Abbott Laboratories in a research report on Friday, July 17th. Leerink Partners cut their price objective on Abbott Laboratories from $119.00 to $106.00 and set a "market perform" rating for the company in a research note on Tuesday, April 21st. JPMorgan Chase & Co. increased their target price on shares of Abbott Laboratories from $110.00 to $120.00 and gave the stock an "overweight" rating in a report on Friday, July 17th. Finally, Robert W. Baird assumed coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They issued an "outperform" rating and a $121.00 price target for the company. Three research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $118.67.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Alphabet AI partnership expands Abbott’s growth opportunity: Abbott and Alphabet announced a multiyear collaboration integrating data from Abbott’s over-the-counter Lingo continuous glucose monitor into the Google Health app. Google’s AI Health Coach is expected to use the data to provide personalized recommendations, potentially increasing Lingo adoption and strengthening Abbott’s position in consumer digital health. Can Abbott Laboratories’ Lingo Partnership With Alphabet Unlock a New Era of AI-Powered Health?
• Positive Sentiment: Wolfe Research upgraded ABT to Outperform: The firm raised its rating from “Peer Perform” and set a $130 price target, implying substantial upside from recent trading levels. The upgrade indicates improving analyst confidence in Abbott’s earnings durability and growth prospects.
• Positive Sentiment: Established Pharmaceuticals remains a growth driver: Abbott’s Established Pharmaceutical Products division is benefiting from emerging-market demand, a broad branded-generics portfolio and biosimilar opportunities. This provides diversification beyond the company’s medical-device businesses. What’s Backing Abbott’s Established Pharmaceuticals Division Growth
• Neutral Sentiment: Recent trading strength reflects broad investor support: Abbott outperformed some medical-product peers during a recent strong market session, while bullish commentary has highlighted the company’s diversified portfolio and long-term growth potential. Abbott Laboratories Stock Outperforms Competitors on Strong Trading Day
• Negative Sentiment: Valuation remains a potential constraint: With a forward-looking earnings multiple above 36 and the stock already well above its recent moving averages, further gains may require continued earnings execution and evidence that newer initiatives such as Lingo can materially contribute to revenue.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source